^
    22h
    Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation (clinicaltrials.gov)
    P2, N=9, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | N=20 --> 9
    Enrollment closed • Enrollment change
    |
    clonoSEQ®
    |
    Opdivo (nivolumab) • Imbruvica (ibrutinib) • cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • fludarabine IV
    23h
    ZeTA: A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T (clinicaltrials.gov)
    P2, N=76, Recruiting, University Health Network, Toronto | Trial completion date: Dec 2027 --> Dec 2029 | Trial primary completion date: Apr 2026 --> Apr 2029
    Trial completion date • Trial primary completion date
    |
    Tevimbra (tislelizumab-jsgr) • Brukinsa (zanubrutinib)
    1d
    AB-HLA-2026: Acalabrutinib Maleate and Bortezomib for Patients With HLA Antibodies (clinicaltrials.gov)
    P3, N=42, Not yet recruiting, The First Affiliated Hospital of Soochow University
    New P3 trial
    |
    bortezomib • Calquence (acalabrutinib)
    1d
    BRUIN-CLL-314: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (clinicaltrials.gov)
    P3, N=737, Recruiting, Loxo Oncology, Inc. | Trial primary completion date: Jun 2025 --> Oct 2027
    Trial primary completion date
    |
    Imbruvica (ibrutinib) • Jaypirca (pirtobrutinib)
    2d
    A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL) (clinicaltrials.gov)
    P1/2, N=106, Completed, Beijing InnoCare Pharma Tech Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    CCND1 (Cyclin D1)
    |
    Chr t(11;14)
    |
    Inokai (orelabrutinib)
    2d
    Composite CLL/SLL and Lymphoplasmacytic Lymphoma with IgM Anti-MAG Neuropathy: Clinicopathologic and Molecular Characterization of a Diagnostically Challenging Case. (PubMed, Ann Clin Lab Sci)
    This case highlights the diagnostic complexity of composite indolent B-cell lymphomas and underscores the importance of integrated clinical, morphologic, immunophenotypic, and molecular assessment to inform management and surveillance.
    Journal • IO biomarker
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD5 (CD5 Molecule) • CD200 (CD200 Molecule) • MME (Membrane Metalloendopeptidase) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    cytarabine • Brukinsa (zanubrutinib)
    2d
    A murine proof-of-concept study of polatuzumab vedotin in combination with venetoclax in experimental therapy of BCL2-positive aggressive lymphomas. (PubMed, Sci Rep)
    POLA demonstrated robust single-agent antitumor activity in vivo, including in PDX models derived from patients with ibrutinib-resistant MCL. This signature likely reflects core pathways associated with POLA resistance and highlights potential novel therapeutic vulnerabilities. These findings strongly support further clinical investigation of POLA in combination with VEN as a BCL2- and MCL1-targeting therapeutic strategy in patients with R/R MCL and BCL2-positive R/R DLBCL.
    Preclinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD79B (CD79b Molecule)
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Polivy (polatuzumab vedotin-piiq)
    2d
    A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies (clinicaltrials.gov)
    P1/2, N=81, Active, not recruiting, Beijing InnoCare Pharma Tech Co., Ltd. | Trial completion date: Jan 2025 --> Jun 2026 | Trial primary completion date: Dec 2023 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    Inokai (orelabrutinib)
    2d
    Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP212525 in Healthy Volunteers (clinicaltrials.gov)
    P1, N=84, Recruiting, Daewoong Pharmaceutical Co. LTD. | Trial completion date: Jun 2026 --> Mar 2027 | Trial primary completion date: Jun 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    3d
    Novel BTK inhibitors and degraders for relapsed/refractory CLL/SLL: latest updates from ASH 2025 annual meeting. (PubMed, J Hematol Oncol)
    Phase 1 studies of docirbrutinib and rocbrutinib demonstrated target engagement across wild-type and resistance-associated BTK mutations with encouraging safety profiles and preliminary efficacy signals in heavily pretreated populations...BTK degraders, including bexobrutideg and BGB-16673, demonstrated rapid and deep responses, activity in high-risk molecular subgroups, and manageable toxicity profiles, with recommended phase 2 doses established. Collectively, these latest updates support continued clinical development of novel agents to address resistance and disease progression in R/R CLL/SLL.
    Journal • IO biomarker
    |
    LYN (LYN Proto-Oncogene Src Family Tyrosine Kinase)
    |
    bexobrutideg (NX-5948) • catadegbrutinib (BGB-16673) • docirbrutinib (AS-1763) • rocbrutinib (LP-168)
    5d
    A Long-term Extension Study of PCI-32765 (Ibrutinib) (clinicaltrials.gov)
    P3, N=700, Recruiting, Janssen Research & Development, LLC | Trial completion date: Aug 2027 --> Dec 2029
    Trial completion date
    |
    Imbruvica (ibrutinib)
    5d
    Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment-Naive Chronic Lymphocytic Leukemia: A Real-World Propensity Score-Matched Study. (PubMed, Cancer Med)
    In real-world practice, venetoclax plus obinutuzumab was associated with longer TTNT and improved OS compared to acalabrutinib as first-line therapy in patients with TP53 wild-type CLL.
    Journal • Real-world evidence • IO biomarker
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • TP53 wild-type
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)